A new study has found that antidepressants provide little to no benefit in treating behavioural and psychological symptoms of dementia, challenging previous assumptions about their effectiveness. The findings, published in the Journal of Psychiatric Research, raise questions about the widespread use of these medications in dementia care and highlight concerns over potential side effects.
Behavioural and psychological symptoms of dementia (BPSD), including agitation, aggression, and depression, are among the most distressing aspects of the condition for both patients and caregivers. While non-drug interventions are recommended as the first line of treatment, antidepressants have been increasingly used as an alternative to antipsychotics, which are known to have serious risks. However, this latest meta-analysis of eight randomised controlled trials, including 676 participants, suggests that antidepressants may not offer significant relief.
The study, which reviewed data from multiple trials, found only a minor reduction in overall BPSD symptoms among those taking antidepressants. However, when trials involving high-dose citalopram were excluded, this improvement disappeared, indicating that the perceived benefits may be largely attributed to specific medications rather than antidepressants as a whole. The study also found no significant impact on agitation, which is one of the most challenging symptoms to manage in dementia patients.
Despite these findings, antidepressants were found to have minimal impact on cognitive function, meaning they did not significantly worsen or improve mental abilities in dementia patients. However, concerns remain over the tolerability of these drugs. The study highlighted an increased risk of side effects such as dizziness, diarrhoea, and, in some cases, heart-related complications. These findings suggest that while antidepressants are generally considered safer than antipsychotics, they are not without risks, particularly for elderly patients with underlying health conditions.
The results challenge the growing reliance on antidepressants for dementia-related symptoms and call for a more cautious approach when prescribing these medications. While some individual drugs, such as citalopram, may show promise at certain dosages, their safety profile remains a concern. This is particularly relevant given that regulatory bodies have advised against high-dose citalopram due to the risk of heart complications.
Experts argue that non-drug treatments, such as tailored behavioural interventions, environmental modifications, and caregiver support, should remain the primary approach for managing BPSD. These interventions, though requiring more resources and time, have been shown to offer benefits without the risks associated with medication.
The study underscores the need for further research to explore safer and more effective treatment options for dementia patients. As the number of people affected by dementia continues to rise, with estimates suggesting 152 million cases worldwide by 2050, the demand for better management strategies will only increase. Clinicians must weigh the limited benefits of antidepressants against their potential risks and consider alternative approaches to ensure the best possible care for patients.
